submit to the journals

Gastrointestinal Oncology Journal Articles, Videos And Insights

Gastrointestinal Oncology:FEATURED Articles

flipper_slider

Gastrointestinal Oncology: Latest Articles

Gastrointestinal Oncology: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Short-acting Calcium Channel Blockers May Double the Risk of Pancreatic Cancer in Postmenopausal Women Katrina Mountfort
Medical Writer, Touch Medical Media, UK
Insight
New Study Recommends Pancreatic Cancer Screening for High-risk Patients Katrina Mountfort, Freelance Medical Writer for Touch Medical Media, UK

Gastrointestinal Oncology:FEATURED VIDEOS

Editor's choice

Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors may play a role in treatment strategies in the near future. 1. What are the major unmet needs in the treatment of colorectal cancer? (0:11) 2. What have been the most important advances in colorectal cancer research in the past year? (0:41) 3. How is personalized medicine impacting the treatment of patients with colorectal cancer? (1:24) 4. What is the rationale for the use of PARP inhibitors in colorectal cancer? (2:14) Speaker disclosures: John L Marshall has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma. 1. What is the latest progress on the clinical development of lenvatinib for the treatment of unresectable hepatocellular carcinoma both in monotherapy and in combination with pembrolizumab? And what is the latest data on lenvatinib in hepatocellular carcinoma at ASCO? (0:11) 2. What is the significance of lenvatinib as a monotherapy for patients with hepatocellular carcinoma? (1:02) 3. What is the rationale for combined therapy with lenvatinib and pembrolizumab? (1:36) 4. Which patients are most likely to benefit from this approach and in what stage of their treatment pathway? (2:04) 5. What in your opinion is the potential for lenvatinib for patients with hepatocellular carcinoma or indeed other tumour patients? (2:29) Speaker disclosures: Jeff Evans has provided consultancy services to Eisai, Bristol-Myers Squibb, Celgene, Bayer and Karus Therapeutics. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Gastrointestinal Oncology:Latest Videos

Video List based on Category on Node Page

Latest Videos

Editorial board member John L Marsahll from The Ruesch Center for the Cure of GI Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center in Washington, DC discusses unmet needs and major advances in the treatment of colorectal cancers, and how PARP inhibitors...
Jeff Evans, of the University of Glasgow, UK, talks to us about the advances in the clinical development of lenvatinib and its potential use in combination with pembrolizumab for the treatment of hepatocellular carcinoma. 1. What is the latest progress on the clinical development of...
Chinthalapally V Rao from the University of Oklahoma Health Sciences Center, Oklahoma City, OK, US, talks to us about the protective role of aspirin and other NSAIDs in colorectal cancer. 1. What is currently known about the protective role of aspirin and other NSAIDs in colorectal...
Sharlene Gill discusses the latest developments in pancreatic cancer and the current treatment guidelines. You can read Dr Gill's latest article on pancreatic cancer here
Marwan Fakih discusses the implications of primary tumour location on biological therapy in metastatic colorectal cancer.
Dr Andrew Hendifar discusses targeting tumor hyaluronan with PEGPH20 (pegvorhyaluronidase alfa) in preclinical models and in human tissue. He discusses the results of the recent phase II study of PEGPH20 in combination with gemcitabine and nab-paclitaxel. This video was supported by...

LATEST TWEETS

Conference Highlights